Aspire Biopharma Holdings, Inc. (ASBP) Financial Ratios
3 years of historical data (2022–2024) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
N/A
—
5yr avg: N/A
ROE
↓
N/A
—
5yr avg: -0.2%
30Y Low-0%·High-0%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Aspire Biopharma Holdings, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Market Cap | $63M | — | — | — |
| Enterprise Value | $64M | — | — | — |
| P/E Ratio → | -5.08 | — | — | — |
| P/S Ratio | — | — | — | — |
| P/B Ratio | — | — | — | — |
| P/FCF | — | — | — | — |
| P/OCF | — | — | — | — |
P/E links to full P/E history page with 30-year chart
EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| EV / Revenue | — | — | — | — |
| EV / EBITDA | — | — | — | — |
| EV / EBIT | — | — | — | — |
| EV / FCF | — | — | — | — |
Profitability
Margins and return-on-capital ratios measuring operating efficiency
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Gross Margin | — | — | — | — |
| Operating Margin | — | — | — | — |
| Net Profit Margin | — | — | — | — |
Return on Capital
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ROE | — | — | -0.2% | -0.2% |
| ROA | -12914.4% | -12914.4% | -0.2% | -0.2% |
| ROIC | — | — | -0.2% | -0.2% |
| ROCE | — | — | -0.2% | -0.2% |
Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Net debt stands at $1M ($1M total debt minus $3633 cash).
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Debt / Equity | — | — | — | — |
| Debt / EBITDA | — | — | — | — |
| Net Debt / Equity | — | — | — | -0.00 |
| Net Debt / EBITDA | — | — | — | — |
| Debt / FCF | — | — | — | — |
| Interest Coverage | -3.46 | -3.46 | -39.99 | — |
Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
The current ratio of 0.09x is below 1.0, meaning current liabilities exceed current assets. The current ratio has declined from 3.62x to 0.09x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Current Ratio | 0.09 | 0.09 | 0.09 | 3.62 |
| Quick Ratio | 0.09 | 0.09 | 0.09 | 3.62 |
| Cash Ratio | 0.00 | 0.00 | 0.02 | 1.64 |
| Asset Turnover | — | — | — | — |
| Inventory Turnover | — | — | — | — |
| Days Sales Outstanding | — | — | — | — |
Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Aspire Biopharma Holdings, Inc. returns 21.9% to shareholders annually primarily through share buybacks.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Dividend Yield | — | — | — | — |
| Payout Ratio | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Earnings Yield | — | — | — | — |
| FCF Yield | — | — | — | — |
| Buyback Yield | 21.9% | — | — | — |
| Total Shareholder Yield | 21.9% | — | — | — |
| Shares Outstanding | — | $48M | $46M | $46M |
Peer Comparison
Compare ASBP with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 ASBPYou | $63M | -5.1 | — | — | — | — | — | — | — |
 CAI | $33B | -6.2 | 718.4 | 496.4 | — | 5.6% | -93.2% | — | 0.0 |
 VCYT | $3B | 44.2 | 44.2 | 22.7 | 70.1% | 11.2% | 5.3% | 4.4% | 0.7 |
 ADPT | $3B | -15.2 | — | — | 59.7% | -90.8% | -62.5% | -41.6% | — |
 NAUT | $331M | -5.6 | — | — | — | — | -32.3% | — | — |
 CDIO | $141M | -0.6 | — | — | 100.0% | -23977.9% | -134.0% | -222.7% | — |
 SEER | $103M | -1.3 | — | — | 49.0% | -717.7% | -23.9% | -21.3% | — |
 IMDX | $95M | -1.2 | — | — | 39.3% | -3245.1% | -1480.7% | — | — |
 YDES | $35M | -15.1 | — | — | 30.4% | -286.5% | -42.7% | -63.3% | — |
 AIMD | $7M | -1.0 | — | — | -153.7% | -66772.2% | -74.4% | -39.8% | — |
 VRAX | $2M | -0.1 | — | — | -838.2% | -97344.8% | -114.4% | -273.2% | — |
| Healthcare Median | — | 23.2 | 14.9 | 19.0 | 65.8% | -6.4% | -36.7% | -13.6% | 3.0 |
Peers based on L4 peer group classification. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 3 years · Updated daily
See ASBP's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ASBP Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare ASBP vs CAI
See how ASBP stacks up against sector leader Caris Life Sciences, Inc..
Start ComparisonFrequently Asked Questions
What is Aspire Biopharma Holdings, Inc.'s P/E ratio?
Aspire Biopharma Holdings, Inc.'s current P/E ratio is -5.1x. This places it at the 50th percentile of its historical range.
Is ASBP stock overvalued?
Based on historical data, Aspire Biopharma Holdings, Inc. is trading at a P/E of -5.1x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.